Louisa Bolm1, Stefan Janssen2, Lukas Käsmann1, Ulrich Wellner3, Tobias Bartscht4, Steven E Schild5, Dirk Rades6. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany. 3. Department of Visceral Surgery, University of Lübeck, Lübeck, Germany. 4. Department of Medical Oncology and Hematology, University of Lübeck, Lübeck, Germany. 5. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 6. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany Rades.Dirk@gmx.net.
Abstract
BACKGROUND/AIM: Patients with metastases from pancreas cancer benefit from individualized care, including radiotherapy for symptom control. To administer the optimal radiation therapy, it is important to understand a patient's prognosis. PATIENTS AND METHODS: Seven variables were analyzed regarding their relationship with survival: age, gender, Karnofsky performance score (KPS), number of metastatic sites, interval from diagnosis of pancreatic cancer to irradiation of metastases, type of irradiated metastasis, and radiation dose. RESULTS: On univariate analysis, survival was positively associated with age ≤ 67 years (p=0.045), KPS >70 (p<0.001), and involvement of only one metastatic site (p=0.013). A longer interval between diagnosis and irradiation of metastases showed a trend for better survival (p=0.077). On multivariate analysis, age [risk ratio (RR)=4.29; p=0.004], KPS (RR=1.95; p=0.020), number of metastatic sites (RR=2.20; p=0.009) and interval to irradiation (RR=4.41; p=0.005) achieved significance. CONCLUSION: The present study identified four independent predictors of survival in patients with pancreatic cancer irradiated for metastasis and thus contributes to treatment optimization. Copyright
BACKGROUND/AIM: Patients with metastases from pancreas cancer benefit from individualized care, including radiotherapy for symptom control. To administer the optimal radiation therapy, it is important to understand a patient's prognosis. PATIENTS AND METHODS: Seven variables were analyzed regarding their relationship with survival: age, gender, Karnofsky performance score (KPS), number of metastatic sites, interval from diagnosis of pancreatic cancer to irradiation of metastases, type of irradiated metastasis, and radiation dose. RESULTS: On univariate analysis, survival was positively associated with age ≤ 67 years (p=0.045), KPS >70 (p<0.001), and involvement of only one metastatic site (p=0.013). A longer interval between diagnosis and irradiation of metastases showed a trend for better survival (p=0.077). On multivariate analysis, age [risk ratio (RR)=4.29; p=0.004], KPS (RR=1.95; p=0.020), number of metastatic sites (RR=2.20; p=0.009) and interval to irradiation (RR=4.41; p=0.005) achieved significance. CONCLUSION: The present study identified four independent predictors of survival in patients with pancreatic cancer irradiated for metastasis and thus contributes to treatment optimization. Copyright
Authors: Mustapha Tehfe; Scot Dowden; Hagen Kennecke; Robert El-Maraghi; Bernard Lesperance; Felix Couture; Richard Letourneau; Helen Liu; Alfredo Romano Journal: Adv Ther Date: 2016-04-16 Impact factor: 3.845